163 related articles for article (PubMed ID: 19744294)
1. The impact of pharmaceutical cost containment policies on the range of medicines available and subsidized in Finland and New Zealand.
Aaltonen K; Ragupathy R; Tordoff J; Reith D; Norris P
Value Health; 2010; 13(1):148-56. PubMed ID: 19744294
[TBL] [Abstract][Full Text] [Related]
2. A 3-dimensional view of access to licensed and subsidized medicines under single-payer systems in the US, the UK, Australia and New Zealand.
Ragupathy R; Aaltonen K; Tordoff J; Norris P; Reith D
Pharmacoeconomics; 2012 Nov; 30(11):1051-65. PubMed ID: 22963187
[TBL] [Abstract][Full Text] [Related]
3. Trends in accessibility to medicines for children in New Zealand: 1998-2002.
Chui J; Tordoff J; Kennedy J; Reith D
Br J Clin Pharmacol; 2004 Mar; 57(3):322-7. PubMed ID: 14998428
[TBL] [Abstract][Full Text] [Related]
4. Access to new medicines in New Zealand compared to Australia.
Wonder M; Milne R
N Z Med J; 2011 Nov; 124(1346):12-28. PubMed ID: 22143849
[TBL] [Abstract][Full Text] [Related]
5. How the Trans Pacific Partnership Agreement could undermine PHARMAC and threaten access to affordable medicines and health equity in New Zealand.
Gleeson D; Lopert R; Reid P
Health Policy; 2013 Oct; 112(3):227-33. PubMed ID: 23992756
[TBL] [Abstract][Full Text] [Related]
6. Patient access to medicines in two countries with similar health systems and differing medicines policies: Implications from a comprehensive literature review.
Babar ZU; Gammie T; Seyfoddin A; Hasan SS; Curley LE
Res Social Adm Pharm; 2019 Mar; 15(3):231-243. PubMed ID: 29678413
[TBL] [Abstract][Full Text] [Related]
7. Changes in availability of paediatric medicines in Australia between 1998 and 2002.
Chui J; Tordoff J; Reith D
Br J Clin Pharmacol; 2005 Jun; 59(6):736-42. PubMed ID: 15948941
[TBL] [Abstract][Full Text] [Related]
8. Improving availability and affordability of plasma-derived medicines.
Cheraghali AM; Abolghasemi H
Biologicals; 2010 Jan; 38(1):81-6. PubMed ID: 20137973
[TBL] [Abstract][Full Text] [Related]
9. Access to children's medicines in the United Kingdom, Australia and New Zealand in 1998, 2002 and 2007.
Ragupathy R; Tordoff J; Norris P; Reith D
Pharm World Sci; 2010 Jun; 32(3):386-93. PubMed ID: 20354788
[TBL] [Abstract][Full Text] [Related]
10. Fighting Excessive Pharmaceutical Prices: Evaluating the Options.
den Exter A
Eur J Health Law; 2020 Apr; 28(1):68-80. PubMed ID: 33652404
[TBL] [Abstract][Full Text] [Related]
11. Uptake of new medicines in New Zealand: evidence of a waiting list.
Barber JM; Sheehy KP
N Z Med J; 2015 Apr; 128(1412):10-20. PubMed ID: 25899488
[TBL] [Abstract][Full Text] [Related]
12. Providing affordable essential medicines to African households: the missing policies and institutions for price containment.
Tetteh Ek
Soc Sci Med; 2008 Feb; 66(3):569-81. PubMed ID: 18023953
[TBL] [Abstract][Full Text] [Related]
13. The Health Impact Fund: incentives for improving access to medicines.
Banerjee A; Hollis A; Pogge T
Lancet; 2010 Jan; 375(9709):166-9. PubMed ID: 20109894
[No Abstract] [Full Text] [Related]
14. Exploring the implications of a fixed budget for new medicines: a study of reimbursement of new medicines in Australia and New Zealand.
Taylor C; Wonder M
Aust Health Rev; 2015 Sep; 39(4):455-461. PubMed ID: 25751688
[TBL] [Abstract][Full Text] [Related]
15. Using national health policies to improve access to palliative care medications in the community.
Rowett D; Ravenscroft PJ; Hardy J; Currow DC
J Pain Symptom Manage; 2009 Mar; 37(3):395-402. PubMed ID: 18722748
[TBL] [Abstract][Full Text] [Related]
16. Government review aims to speed up NHS access to new medicines.
Hawkes N
BMJ; 2014 Nov; 349():g7090. PubMed ID: 25422172
[No Abstract] [Full Text] [Related]
17. How to solve financing gap to ensure patient access to patented pharmaceuticals in CEE countries? - the good, the bad, and the ugly ways.
Inotai A; Kaló Z
Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):627-632. PubMed ID: 31810392
[No Abstract] [Full Text] [Related]
18. Comparing subsidized access to medicines across payer systems.
Wonder M; Milne R
Pharmacoeconomics; 2013 Feb; 31(2):173-4. PubMed ID: 23329425
[No Abstract] [Full Text] [Related]
19. Preferences on policy options for ensuring the financial sustainability of health care services in the future: results of a stakeholder survey.
Tordrup D; Angelis A; Kanavos P
Appl Health Econ Health Policy; 2013 Dec; 11(6):639-52. PubMed ID: 24129648
[TBL] [Abstract][Full Text] [Related]
20. The authors' reply to wonder and milne: "comparing subsidized access to medicines across payer systems".
Ragupathy R; Aaltonen K; Tordoff J; Norris P; Reith D
Pharmacoeconomics; 2013 Feb; 31(2):175-6. PubMed ID: 23329428
[No Abstract] [Full Text] [Related]
[Next] [New Search]
